Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...
GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
VANCOUVER, Washington, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized ...
CytoDyn (CYDY) announced that breast cancer specialist and medical oncologist, Milana V. Dolezal, MD, MSci, is presenting a poster entitled “Prolonged survival following PD-L1/PD-1 immune checkpoint ...
First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...
Common Metabolic Enzyme Could Predict Cancer Immunotherapy Benefits — and Help More Patients Respond
A Rutgers Cancer Institute study in Cell Reports Medicine promises help with both those problems. It identifies a protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results